Regulatory snapshots, including drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations in Asia-Pacific, including: Apogenix, Ascletis, Aytu Bioscience, Calidi, Celltrion, Direct Biologics, Edesa, Eisai, Merck, Foresee, Hutchison China Meditech, Poxel, Sumitomo Dainippon, Realta Life Sciences, Relief, Neurorx, Revive, Sound, Takeda, Teva.